methyl (pyridin-2-ylcarbamoyl)formate | 54166-60-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl (pyridin-2-ylcarbamoyl)formate
• 英文别名: methyl 2-oxo-2-(pyridin-2-ylamino)acetate；(2-Pyridyl)-oxamsaeure-methylester；pyridin-2-yl-oxalamic acid methyl ester；(2-Pyridyl)oxamic acid methyl ester；Methyl 2-Oxo-2-(2-pyridinylamino)acetate
• CAS: 54166-60-8
• 化学式: C₈H₈N₂O₃
• mdl: MFCD00966534
• 分子量: 180.163
• InChiKey: UUBNUXNGZWIWGU-UHFFFAOYSA-N

物化性质

• 熔点：
  102-106 °C(Solv: ethyl ether (60-29-7))
• 密度：
  1.327±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  68.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl (pyridin-2-ylcarbamoyl)formate 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 生成 2-(2-methoxy-2-oxoacetamido)pyridine 1-oxide
  参考文献：
  名称：

  含富马酰乙酰乙酸水解酶结构域蛋白 1 (FAHD1) 的抑制剂

  摘要：

  含有 FAH 结构域的蛋白 1 (FAHD1) 在线粒体中充当草酰乙酸脱羧酶，有助于三羧酸循环的调节。以草酸配体的 FAHD1 的高分辨率 X 射线结构为指导，详细分析了底物处理的酶促机制。考虑到 FAHD1 底物草酰乙酸的化学特征，推断出潜在的抑制剂结构。药物样支架的合成提供了第一代 FAHD1 抑制剂，其活性在低微摩尔 IC 50范围内。研究揭示了与底物竞争结合金属辅因子的结构，以及支架，它们可能具有与 FAHD1 的新结合模式。

  DOI：

  10.3390/molecules26165009
• 作为产物：
  描述：

  2-氨基吡啶 、 甲基戊酰氯 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 生成 methyl (pyridin-2-ylcarbamoyl)formate
  参考文献：
  名称：

  轻度铜催化羟基化反应发展的试剂设计和配体演化

  摘要：

  模块化配体库的并行合成和质量导向纯化，高通量实验和合理的配体演化，已经导致了一种新型的铜催化剂，可用于合成具有无痕氢氧化物的苯酚。此处报道的温和的反应条件使许多复杂的类药物酚的后期合成成为可能。

  DOI：

  10.1021/acs.orglett.7b01403

文献信息

• First-in-Class Pan Caspase Inhibitor Developed for the Treatment of Liver Disease
  作者：Steven D. Linton、Teresa Aja、Robert A. Armstrong、Xu Bai、Long-Shiuh Chen、Ning Chen、Brett Ching、Patricia Contreras、Jose-Luis Diaz、Craig D. Fisher、Lawrence C. Fritz、Patricia Gladstone、Todd Groessl、Xin Gu、Julia Herrmann、Brad P. Hirakawa、Niel C. Hoglen、Kathy G. Jahangiri、Vincent J. Kalish、Donald S. Karanewsky、Lalitha Kodandapani、Joseph Krebs、Jeff McQuiston、Steven P. Meduna、Kip Nalley、Edward D. Robinson、Robert O. Sayers、Kristen Sebring、Alfred P. Spada、Robert J. Ternansky、Kevin J. Tomaselli、Brett R. Ullman、Karen L. Valentino、Suzanne Weeks、David Winn、Joe C. Wu、Pauline Yeo、Cheng-zhi Zhang

  DOI：10.1021/jm050307e

  日期：2005.11.1

  A series of oxamyl dipeptides were optimized for pan caspase inhibition, anti-apoptotic cellular activity and in vivo efficacy. This structure-activity relationship study focused on the P4 oxamides and warhead moieties. Primarily on the basis of in vitro data, inhibitors were selected for study in a murine model of alpha-Fas-induced liver injury. IDN-6556 (1) was further profiled in additional in vivo

  针对泛半胱天冬酶抑制，抗凋亡细胞活性和体内功效优化了一系列草酰二肽。这项结构-活性关系研究的重点是P4乙酰胺和弹头部分。主要根据体外数据，在α-Fas诱导的肝损伤小鼠模型中选择抑制剂进行研究。IDN-6556（1）在其他体内模型和药代动力学研究中得到了进一步的描述。现在，这种一流的胱天蛋白酶抑制剂已成为两项II期临床试验的主题，评估了其在肝病中使用的安全性和有效性。
• Pyridyl oxamic acid derivatives and use in the prevention of allergic
  申请人：American Home Products Corporation

  公开号：US04054661A1

  公开（公告）日：1977-10-18

  Anti-allergic agents of aromatic and heterocyclic oxamic acid derivation present the following formula: ##STR1## in which A is a member selected from the group consisting of 2-thiazolyl, 2-pyridyl, 2-pyridyl-N-oxide, 6-(lower)alkyl-2-pyridyl, 3-cyano-2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 2-pyrazinyl, .alpha.-naphthyl, .beta.naphthyl, phenyl, 2,6-dichlorophenyl, and substituted phenyl moieties containing from one to three substituents in any of the 2,3,4 and 5 positions of the phenyl ring, independently selected from the group consisting of lower alkyl, lower alkylthio, lower alkylsulfinyl, lower alkoxy, hydroxy(lower)-alkoxy, 2-(lower alkoxy oxalyloxy) ethoxy, benzyloxy, N-mono-and di-lower alkylamino(lower)-alkoxy, halo, sulfamyl, polyhalo(lower)alkyl, carbamyl, N-lower alkylcarbamyl, nitro, mono-and di-lower alkylamino, phenylazo, carboxy, lower alkylcarbonyl, cyano, carb(lower)alkoxy, phenoxy(lower)alkoxy, lower alkoxyoxalamido and lower alkoxyoxalamidophenoxy radicals; B, when taken alone, is a member selected from the group consisting of --OH, lower alkoxy, --NH.sub.2, --NHOH, cyclohexyloxy and phenoxy; and Y is a member selected from the group consisting of oxygen and when taken with B and the carbon atom to which they are attached, forms the moiety ##STR2##

  芳香族和杂环氧酰胺衍生的抗过敏剂具有以下公式：##STR1## 其中A是从2-噻唑基，2-吡啶基，2-吡啶基-N-氧化物，6-（较低）烷基-2-吡啶基，3-氰基-2-吡啶基，3-吡啶基，4-吡啶基，2-吡嘧啶基，2-吡嗪基，α-萘基，β-萘基，苯基，2,6-二氯苯基和取代苯基中选择的一种成员，所述取代苯基包含一个到三个取代基，所述取代基独立地选择自较低烷基，较低硫代烷基，较低磺代烷基，较低烷氧基，羟基（较低）-烷氧基，2-（较低烷氧基氧乙酰氧基）乙氧基，苄氧基，N-单和二-较低烷基氨基（较低）-烷氧基，卤，磺酰胺，多卤（较低）烷基，氨基甲酰，N-较低烷基氨基甲酰，硝基，单和二-较低烷基氨基，苯基偶氮，羧基，较低烷基羰基，氰基，羰基（较低）烷氧基，苯氧基（较低）烷氧基，较低烷氧基草酰胺基和较低烷氧基草酰胺基苯氧自由基；B，单独时，是从-OH，较低烷氧，-NH.sub.2，-NHOH，环己氧基和苯氧基中选择的一种成员；Y是从氧中选择的一种成员，当与B和它们连接的碳原子一起被选取时，形成如下部分：##STR2##
• Oxamic acid derivatives
  申请人：American Home Products Corporation

  公开号：US04160100A1

  公开（公告）日：1979-07-03

  Anti-allergic agents of aromatic and heterocyclic oxamic acid derivation present the following formula: ##STR1## in which A is a member selected from the group consisting of 2-thiazolyl, 2-pyridyl, 2-pyridyl-N-oxide, 6-(lower)alkyl-2-pyridyl, 3-cyano-2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 2-pyrazinyl, .alpha.-naphthyl, .beta.-naphthyl, phenyl, 2,6-di-chlorophenyl, and substituted phenyl moieties containing from one to three substituents in any of the 2,3,4 and 5 positions of the phenyl ring, independently selected from the group consisting of lower alkyl, lower alkylthio, lower alkylsulfinyl, lower alkoxy, hydroxy(lower)alkoxy, 2-(lower alkoxy oxalyloxy) ethoxy, benzyloxy, N-mono-and di-lower alkylamino(lower)alkoxy, halo, sulfamyl, polyhalo(lower)alkyl, carbamyl, N-lower alkylcarbamyl, nitro, mono-and di-lower alkylamino, phenylazo, carboxy, lower alkylcarbonyl, cyano, carb(lower)alkoxy, phenoxy(lower)alkoxy, lower alkoxyoxalamido and lower alkoxyoxalamidophenoxy radicals; B, when taken alone, is a member selected from the group consisting of --OH, lower alkoxy, --NH.sub.2, --NHOH, cyclohexyloxy and phenoxy; and Y is a member selected from the group consisting of oxygen and when taken with B and the carbon atom to which they are attached, forms the moiety ##STR2##

  芳香族和杂环氧酰胺衍生的抗过敏剂具有以下化学式：##STR1## 其中A是从以下组中选择的成员：2-噻唑基、2-吡啶基、2-吡啶-N-氧化物、6-（较低）烷基-2-吡啶基、3-氰基-2-吡啶基、3-吡啶基、4-吡啶基、2-嘧啶基、2-吡嗪基、α-萘基、β-萘基、苯基、2,6-二氯苯基和含有1至3个取代基的取代苯基，这些取代基独立地选自下列组成的组：较低烷基、较低烷硫基、较低烷基亚硫酰基、较低烷氧基、羟基（较低）烷氧基、2-（较低烷氧羰酰氧基）乙氧基、苄氧基、N-单和双较低烷基氨基（较低）烷氧基、卤素、磺酰基、多卤素（较低）烷基、氨基甲酰基、N-较低烷基甲酰基、硝基、单和双较低烷基氨基、苯基偶氮基、羧基、较低烷基羰基、氰基、羰（较低）烷氧基、苯氧基（较低）烷氧基、较低烷氧羰胺基和较低烷氧羰胺苯氧基基团；B单独时，是从以下组成的组中选择的成员：--OH、较低烷氧、--NH.sub.2、--NHOH、环己氧基和苯氧基；Y是从以下组成的组中选择的成员：氧，当与B和它们连接的碳原子一起取得时，形成如下团 ##STR2##
• Oxamic acid derivatives for the prevention of immediate type
  申请人：American Home Products Corporation

  公开号：US03966965A1

  公开（公告）日：1976-06-29

  Anti-allergic agents of ##EQU1## and heterocyclic oxamic acid derivation present the following formula: IN WHICH A is a member selected from the group consisting of 2-thiazolyl, 2-pyridyl, 2-pyridyl-N-oxide, 6-(lower)alkyl-2-pyridyl, 3-cyano-2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 2-pyrazinyl, .alpha.-naphthyl, .beta.-naphthyl, phenyl, 2,6-dichlorophenyl, and substituted phenyl moieties containing from one to three substituents in any of the 2,3,4 and 5 positions of the phenyl ring, independently selected from the group consisting of lower alkyl, lower alkylthio, lower alkylsulfinyl, lower alkoxy, hydroxy(lower)-alkoxy, 2-(lower alkoxy oxalyloxy) ethoxy, benzyloxy, N-mono-and di-lower alkylamino(lower)-alkoxy, halo, sulfamyl, polyhalo(lower)alkyl, carbamyl, N-lower alkylcarbamyl, nitro, mono- and di-lower alkylamino, phenylazo, carboxy, lower alkylcarbonyl, cyano, carb(lower)alkoxy, phenoxy(lower)alkoxy, lower alkoxyoxalamido and lower alkoxyoxalamidophenoxy radicals; B, when taken alone, is a member selected from the group consisting of -OH, lower alkoxy, --NH.sub.2, --NHOH, cyclohexyloxy and phenoxy; and Y is a member selected from the group consisting of oxygen and when taken with B and the carbon atom to which they are attached, forms the moiety ##EQU2##

  ##EQU1##的抗过敏剂和杂环氧酰胺衍生物具有以下公式：其中A是从2-噻唑基，2-吡啶基，2-吡啶-N-氧化物，6-（较低）烷基-2-吡啶基，3-氰基-2-吡啶基，3-吡啶基，4-吡啶基，2-吡嘧啶基，2-吡啶基，α-萘基，β-萘基，苯基，2,6-二氯苯基和取代苯基等组成的群中选择的成员，其中该苯环的2,3,4和5位置中的任意位置都包含从一个到三个取代基的取代基，这些取代基独立地从较低烷基，较低硫代烷基，较低磺酰基，较低烷氧基，羟基（较低）-烷氧基，2-（较低烷氧基氧代羰基）乙氧基，苄氧基，N-单和二-较低烷基氨基（较低）-烷氧基，卤素，磺酰基，多卤代（较低）烷基，氨基甲酰基，N-较低烷基氨基甲酰基，硝基，单和双-较低烷基氨基，苯基偶氮基，羧基，较低烷基羰基，氰基，羰基（较低）烷氧基，苯氧基（较低）烷氧基，较低烷氧氧代草酰胺基和较低烷氧氧代草酰胺苯氧基自由基；B，当单独取时，是从-OH，较低烷氧基，-NH.sub.2，-NHOH，环己氧基和苯氧基等组成的群中选择的成员；Y是从氧中选择的成员，当与B和它们连接的碳原子一起取时，形成上述公式。
• Photochemical and DNA degradation studies on tenoxicam, lornoxicam, and their photolysis products
  作者：Ibrahim Elghamry、Usama El-Ayaan、Magdy M. Youssef、Shar Al-Shihry、Matthias Letzel、Jochen Mattay

  DOI：10.1007/s00706-016-1765-z

  日期：2017.2

  AbstractTenoxicam and lornoxicam are nonsteroidal anti-inflammatory drugs, were subjected to photoirradiation at 254 nm led to the photodegradation of the pharmaceutical agents. Both, the isolated photodegradation products and the pharmaceutical agents were examined toward DNA binding and degradation. The photodegradation products degrade calf thymus in concentration dependent manner. Graphical abstract

  AbstractTenoxicam and lornoxicam are nonsteroidal anti-inflammatory drugs, were subjected to photoirradiation at 254 nm led to the photodegradation of the pharmaceutical agents. Both, the isolated photodegradation products and the pharmaceutical agents were examined toward DNA binding and degradation. The photodegradation products degrade calf thymus in concentration dependent manner. Graphical abstract